首页> 美国卫生研究院文献>other >Immunization Against Group B Streptococci vs. Intrapartum Antibiotic Prophylaxis in Peripartum Pregnant Women and their Neonates: A Review
【2h】

Immunization Against Group B Streptococci vs. Intrapartum Antibiotic Prophylaxis in Peripartum Pregnant Women and their Neonates: A Review

机译:围产期孕妇及其新生儿对B组链球菌与产前抗生素预防的免疫研究:综述

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Group B streptococcus (GBS) is an organism that has an immense global impact on neonatal morbidity and mortality. GBS is known to colonize the gastrointestinal and genitourinary tracts of infected pregnant women. Transmission to the neonate is achieved during labor and delivery. Complications of neonatal infection include sepsis, meningitis, and pneumonia. Preventative measures are needed to reduce the disease burden. The current method of prophylaxis being utilized is intrapartum antibiotics. Though effective, it presents limitations that include a required, lengthy duration of treatment, increased antibiotic resistance, and lack of late-onset disease coverage. Recent studies are exploring alternative methods of prophylaxis such as vaccination. Vaccination provides coverage of both early and late-onset disease to infected women who are unable to complete the required four hours of antibiotic course intrapartum, women with resistance to antibiotic infections, and women delivering in resource-poor areas without access to antibiotics. An investigational CRM197 conjugated trivalent vaccine has shown a good immunogenicity profile against the three most prevalent serotypes. The vaccine induced antibodies freely cross the placenta and persist in a neonate for up to 90 days after birth. Additionally, the vaccine possesses a safety profile free of any serious systemic adverse effects and only mild pain at the injection site. Future studies should focus on investigating the effect of the vaccine on maternal rectovaginal acquisition and subsequent vaginal colonization, as well as the expansion of vaccine coverage to all 10 serotypes identified worldwide in order to facilitate its use in resource-poor areas of the world with inadequate antibiotic availability. If available, such a vaccine can serve as an effective supplement to current guidelines of antibiotic prophylaxis against GBS in peripartum women and their neonates.
机译:B组链球菌(GBS)是一种对新生儿发病率和死亡率具有巨大全球影响的生物。已知GBS会定植感染孕妇的胃肠道和泌尿生殖道。可以在分娩和分娩期间传播给新生儿。新生儿感染的并发症包括败血症,脑膜炎和肺炎。需要采取预防措施以减轻疾病负担。目前使用的预防方法是产时使用抗生素。尽管有效,但存在局限性,包括所需的治疗时间长,抗生素耐药性增加以及缺乏晚发性疾病的覆盖范围。最近的研究正在探索其他预防方法,例如疫苗接种。疫苗接种为无法完成必要的四个小时产程内抗生素疗程的感染妇女,对抗生素感染有抵抗力的妇女以及在资源贫乏地区无法获得抗生素的妇女提供了早发和晚发疾病的保险。研究型CRM197共轭三价疫苗已显示出针对三种最普遍的血清型的良好免疫原性。疫苗诱导的抗体可自由穿过胎盘,并在新生儿出生后可持续长达90天。另外,该疫苗的安全性没有任何严重的全身性不良反应,注射部位仅有轻度疼痛。未来的研究应侧重于研究该疫苗对孕产妇直肠阴道采集和随后的阴道定植的影响,以及将疫苗的覆盖面扩大到全世界确定的所有10种血清型,以促进其在世界上资源贫乏地区的使用不足抗生素的可用性。如果可以的话,这种疫苗可以作为围产期妇女及其新生儿针对GBS的现行抗生素预防指南的有效补充。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号